| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $358K | — | — |
| R&D Expense | $13.2M | — | +11.6% |
| SG&A Expense | $8.1M | — | -32.1% |
| Operating Income | -$20.9M | — | +23.2% |
| Income Tax | $0 | — | — |
| Net Income | -$19.9M | — | -160.9% |
| EPS (Basic) | -$2.08 | — | -155.3% |
| EPS (Diluted) | -$2.08 | — | -155.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $29.8M | -34.8% | -49.3% |
| Accounts Receivable | $233K | +48.4% | — |
| Current Assets | $31.8M | -35.5% | -51.8% |
| Total Assets | $117.6M | -14.9% | -28.4% |
| Current Liabilities | $19.3M | +0.1% | -38.2% |
| Total Liabilities | $91.1M | -3.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$16.4M | — | -160.8% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | $0 | — | +100.0% |
| Financing Cash Flow | $428K | — | -63.7% |
| Free Cash Flow | -$16.4M | — | -160.9% |
| -19.9% |
| Stockholders' Equity | $26.5M | -40.1% | -47.5% |